Mirum and Incyte’s Atebrioz approved for FOP in US
The US Food and Drug Administration (FDA) has approved Mirum Pharmaceuticals and Incyte’s Atebrioz (zilurgisertib) for the treatment of fibrodysplasia ossificans progressiva (FOP) in patients aged 12 and above.
Read the full article on the original site.
Read Full Article